A research team from the University of Chicago have studied the three dimensional structure of a cell receptor molecule which is related to the development of various diseases like melanoma, leukemia and brain disorders like frontoparietal polymicrogyria.
The research study based on the protein molecule which provides a framework for developing new pharmaceutical treatment for diseases was published in the journal Neuron.
Gabriel Salzman, an MD/PhD student in the Biophysical Sciences Graduate Program at the University of Chicago, says "Given the complicated biology mediated by aGPCRs, particularly in neurodevelopment, we believe our work will pave the way for future studies investigating the molecular details of these important processes, bringing us closer to the ultimate goal of combatting diseases influenced by aGPCRs."
Salzman study focussed on the extracellular region of GPCR which is also known as GPR56 or ADGRG1 which was found to play a major role in the muscle cell , cancer and neurodevelopment. GPR56 plays a role in developing the cortex cells and oligodendrocytes.
The project was carried out by Salzman along with Demet Arac, PhD, and Shohei Koide, PhD to study about targeting the extracellular region of GPCR for pharmaceutical development.
The study focused on a unique protein domain called PLL, and when deleted would increase cell signaling.
Bioinformatic analysis helps to identify a particular position in PLL domain and also estimated the role of this domain in GPR56. Understanding the role of this domain would help in finding new solutions for the treatment of various diseases mediated by proteins.
Salzman further added that, "Our discovery that aG-Protein Coupled Receptor extracellular regions regulate function in a multifaceted and complex manner provides important guidelines for developing therapeutics for diverse diseases in which aGPCRs play important roles".